HF
PDLI

Hoxton Financial’s PDL BioPharma, Inc. PDLI Stock Holding History

Hoxton Financial’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,398
Closed -$12K – 735
2013
Q4 		$12K Buy
1,398
+399
+40% +$3.36K 0.01% 441
2013
Q3 		$8K Sell
999
-14
-1% -$113 0.01% 306
2013
Q2 		$8K Buy
+1,013
New +$7.9K ﹤0.01% 446

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hoxton Financial's PDLI Position: Q1 2014 in Review

Hoxton Financial sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 1,398 shares — an estimated $12K sold.

Hoxton Financial first reported a position in PDLI in Q2 2013 and held it in 3 quarters. The position peaked at $12K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Hoxton Financial reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Hoxton Financial sold 1,398 PDL BioPharma, Inc. shares in Q1 2014, an estimated $12K.
  • Hoxton Financial first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 3 quarters.
  • Hoxton Financial's PDL BioPharma, Inc. position peaked at $12K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Hoxton Financial's 13F filing for Q1 2014, filed 25 Apr 2014.